{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ACHC",
  "name": "Acadia Healthcare Company, Inc.",
  "url": "https://orbyd.app/dossiers/ACHC/",
  "json_url": "https://orbyd.app/dossiers/ACHC.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-scandal behavioral-health turnaround re-rate now cluster-confirmed: UBS $39, Keybanc $40, Guggenheim $38, TD Cowen $36 all lifted above the old $30.20 high in 11 days, driving a breakout to ~$34.50. The 2026-07-28 Q2 print (Florida DPP the swing line) is the binary — accelerating but extended, ~29% short, and shadowed by an open DOJ/SEC probe. Don't chase into the print.",
  "invalidation_trigger": "A weekly close below $30 surrenders the breakout above the $30.20 prior 52-week high and turns the sell-side re-rate into a failed breakout; independently broken by a DOJ/SEC charging or consent-decree 8-K, the $105M verdict upheld on appeal, or the 2026-07-28 Q2 print holding FY26 guidance flat despite Florida DPP.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Last confirmed price $23.50 (2026-06-17), market cap ~$2.25B; 52-wk range $11.43–$30.20; June high ~$26.84. Re-validate spot post-UBS-$39 before trusting levels.",
    "Q2 2026 earnings 2026-07-28 after close; call 2026-07-29 9:00 a.m. ET. Three-trading-day pre-print blackout applies — avoid fresh entries into the binary.",
    "Florida Directed Payment Program contribution is the single watched line; a beat without DPP color or a flat FY26 guide fails the breakout above $30.20.",
    "DOJ + SEC probe (DOJ grand-jury subpoena disclosed 2024) unresolved per the 2025 annual report; a charging decision or consent-decree 8-K is a discrete -20%+ single-session tail independent of price/technicals.",
    "$105M jury verdict 2026-05-12 (Fashion Valley CTC: $35M compensatory + $70M punitive) under appeal; separate from the federal probe. Distinct closed items: ~$20M Medicare settlement (2024) and ~$179M investor securities settlement.",
    "Legacy turnaround led by returning CEO Debra Osteen. Do NOT average down — value-trap profile if the breakout fails and price loses the low-$20s base ($22.66).",
    "Leading PT cluster $36–40 vs lagging $29 consensus average; 8 Buy / 6 Hold / 1 Sell. Stock ~$34.50 (2026-07-26) already above the average target — most of the easy re-rate is priced.",
    "Re-engage only on post-print structure: a confirmed DPP beat holding a weekly close above ~$34–35, or a pullback that holds the $30.20 breakout retest on volume."
  ],
  "body_markdown": "## Current Thesis\nThe behavioral-health turnaround that began printing in Q1 has gone from a single analyst's call to a full sell-side re-rate, and the tape has followed: ACHC trades near $34.50 (2026-07-26), a fresh 52-week high above the prior $30.20 ceiling. In eleven days four desks lifted targets in unison — UBS to $39 (2026-07-09), Keybanc to $40 and TD Cowen to $36 (both 2026-07-14), Guggenheim to $38 (2026-07-20) — every one above the old high, underwriting the raised FY26 guide and the Florida Directed Payment Program upside rather than the bounce off the $11.43 low. Returning CEO Debra Osteen's operating reset is the story the Street is buying. The catch is timing: Q2 lands after the close on 2026-07-28 (call 2026-07-29), two sessions out, and it is the whole thesis test — Florida DPP is the line that either extends the breakout or fails it. With ~29% of the float short and the stock already up ~40% since early June, the narrative is accelerating but stretched into a binary event still shadowed by an open DOJ/SEC probe. A fresh entry the day before the print is chasing extension into an event; the cleaner engagement is the post-print reaction.\n\n## Bull Case\n- **Sell-side cluster above the old high:** UBS $39 (2026-07-09), Keybanc $40 and TD Cowen $36 (2026-07-14), Guggenheim $38 (2026-07-20) — four raises in eleven days, all above the $30.20 52-week high, with the leading band now $36–40 versus a lagging $29 consensus average that has yet to catch up.\n- **Clean Q1 + raised FY26 guide (2026-04-29):** revenue $828.8M (+7.6% YoY); same-facility revenue +7.3% (1.6% more patient days, 5.6% higher revenue/day); acute inpatient psych $470.7M (+14% YoY). FY26 guide lifted to revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60.\n- **Concrete Q2 bar:** management guided Q2 to revenue $835–850M / adj. EBITDA $142–152M / adj. EPS $0.30–0.40 — the measurable line the 2026-07-28 print is judged against, with Florida DPP the swing factor flagged as a further guide-raise trigger.\n- **~29% short interest into a confirmed guide raise:** a heavily short float turns any Q2 beat or DPP approval into forced covering on top of fundamental buying.\n- **Capacity + cash inflection:** 275 facilities / ~12,400 beds across 40 states + Puerto Rico (2026-03-31), ~84,000 patients daily; 400–600 net new beds planned in 2026 while cutting capex $300M+ versus 2025, with two JV beds opening in Q2 (144-bed Orlando Health; 96-bed Methodist Jennie Edmundson, Iowa).\n- **Management credibility:** the re-rate is anchored to returning CEO Debra Osteen, the operator the Street associates with Acadia's prior growth run.\n\n## Bear Case\n- **DOJ + SEC probe still open:** unresolved per the 2025 annual report; a DOJ grand-jury subpoena (disclosed 2024) and an SEC inquiry remain live, with $135M of legal fees run through 2025. A charging decision or consent decree is a single-session -20%+ tail no guide raise offsets. The closed 2024 ~$20M Medicare settlement and a separate ~$179M investor securities settlement did not resolve it.\n- **$105M jury verdict (2026-05-12):** subsidiary Fashion Valley CTC hit with $35M compensatory + $70M punitive in a retaliatory-termination case; management is pursuing post-trial motions and appeal but concedes no assurance damages shrink.\n- **Extended into a binary:** ~$34.50 is roughly +40% off the early-June ~$24.48 and near 3x the $11.43 low, above the $29 consensus average and pressing the lower bound of the $36–40 leading targets. Most of the re-rate is priced; further upside now depends on the print itself.\n- **The whole thesis is one line:** if Florida DPP doesn't show and Q2 guidance holds flat, the breakout above $30.20 becomes a bull trap, and a heavily short, extended name gaps the other way.\n- **Consensus is split:** 8 Buy / 6 Hold / 1 Sell — the enthusiasm is real but not unanimous, and the Holds anchor to the legal overhang the bulls are discounting.\n\n## Setup & Price Structure\n- **Breakout confirmed, extended:** after digesting the mid-$20s through June (June high ~$26.84, fade to $23.50 on 2026-06-17), the mid-July upgrade wave carried ACHC through the $30.20 52-week high to ~$34.50 (2026-07-26) — a clean move to new highs running well above its rising moving averages after a ~40% seven-week advance.\n- **Support ladder:** first retest is the prior $30.20 high (now would-be support); below that the June recovery base near $22.66; the $11.43 low is the distant floor.\n- **Resistance / targets:** the leading PT band $36–40 sits just overhead; with no prior price history above $30.20, the tape is in discovery.\n- **Squeeze mechanics:** ~29% short interest is the accelerant — constructive on a beat, but it cuts both ways if the print disappoints and shorts press a failed breakout.\n- **Trap read:** the narrative is accelerating and cluster-confirmed, yet the entry sits two sessions before a binary print, at new highs, above the average target — buying here is chasing extension into an event, not stepping onto a base. The disciplined stance is to let the print clear and engage the reaction.\n\n## Catalyst Calendar (next 30 days)\n\n- **Rolling:** further sell-side revisions likely in the 48 hours after the print as desks mark to the DPP number; DOJ/SEC probe headlines remain an unscheduled tail through the window.\n\n## Elapsed catalysts\n\n- **2026-07-28 (after close):** Q2 2026 earnings release — the binary. Bar is revenue $835–850M / adj. EBITDA $142–152M / adj. EPS $0.30–0.40; Florida DPP contribution and any FY26 guide revision are the watched lines. Three-trading-day pre-print blackout applies. *(passed 12d ago)*\n- **2026-07-29, 9:00 a.m. ET:** Q2 earnings conference call — DPP color, bed-additions cadence, and any legal-timeline commentary. *(passed 11d ago)*\n\n## What Would Change Our Mind\n- **Bull confirmation:** a Q2 beat with an explicit Florida DPP contribution and a raised FY26 guide, holding the breakout with a weekly close above ~$34–35, validates the $36–40 targets and re-opens engagement on strength.\n- **Thesis break:** a weekly close below $30 surrenders the breakout above the $30.20 prior high and turns the re-rate into a failed breakout; a close under the $22.66 June base confirms a full structure break.\n- **Discrete kill:** a DOJ/SEC charging decision or consent-decree 8-K, or the $105M verdict upheld/expanded on appeal — either is a step-change in the legal tail independent of price.\n- **Guide failure:** a Q2 print holding FY26 guidance flat despite DPP removes the reason the sell-side cluster moved above the old high.\n\n## Correlation Notes\n- **Facility-based behavioral peers:** moves with UHS and other psychiatric/facility operators on reimbursement and directed-payment-program headlines; the Florida DPP read-through is name-specific, but Medicaid supplemental-payment policy is a shared driver.\n- **Policy beta:** Medicaid rate and DPP policy, plus any federal behavioral-health funding shift, drive the group more than broad market beta — a low-beta defensive-health name whose dominant risk is legal rather than macro.\n- **Short-squeeze cohort:** the ~29% short interest ties near-term intraday behavior to squeeze dynamics more than to sector flows into the print.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-07-26T11:19:53+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}